Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gamida Cell stock

Own Gamida Cell stock in just a few minutes.

Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 110 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Gamida Cell

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GMDA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Gamida Cell share price

Use our graph to track the performance of GMDA stocks over time.

Gamida Cell shares at a glance

Information last updated 2021-04-29.
52-week range$3.86 - $12.47
50-day moving average $8.13
200-day moving average $8.10
Wall St. target price$19.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.20

Buy Gamida Cell shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Gamida Cell stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gamida Cell financials

Gross profit TTM $0
Return on assets TTM -34.73%
Return on equity TTM -108.74%
Profit margin 0%
Book value $1.67
Market capitalisation $447.3 million

TTM: trailing 12 months

Shorting Gamida Cell shares

There are currently 1.5 million Gamida Cell shares held short by investors – that's known as Gamida Cell's "short interest". This figure is 7.7% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting Gamida Cell shares can be evaluated.

Gamida Cell's "short interest ratio" (SIR)

Gamida Cell's "short interest ratio" (SIR) is the quantity of Gamida Cell shares currently shorted divided by the average quantity of Gamida Cell shares traded daily (recently around 379906.93069307). Gamida Cell's SIR currently stands at 4.04. In other words for every 100,000 Gamida Cell shares traded daily on the market, roughly 4040 shares are currently held short.

However Gamida Cell's short interest can also be evaluated against the total number of Gamida Cell shares, or, against the total number of tradable Gamida Cell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gamida Cell's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Gamida Cell shares in existence, roughly 30 shares are currently held short) or 0.031% of the tradable shares (for every 100,000 tradable Gamida Cell shares, roughly 31 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gamida Cell.

Find out more about how you can short Gamida Cell stock.

Gamida Cell share dividends

We're not expecting Gamida Cell to pay a dividend over the next 12 months.

Gamida Cell share price volatility

Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $3.86 up to $12.47. A popular way to gauge a stock's volatility is its "beta".

GMDA.US volatility(beta: 1.97)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 1.9728. This would suggest that Gamida Cell's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Gamida Cell overview

Gamida Cell Ltd. , a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site